ATE62419T1 - Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten. - Google Patents

Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.

Info

Publication number
ATE62419T1
ATE62419T1 AT88105821T AT88105821T ATE62419T1 AT E62419 T1 ATE62419 T1 AT E62419T1 AT 88105821 T AT88105821 T AT 88105821T AT 88105821 T AT88105821 T AT 88105821T AT E62419 T1 ATE62419 T1 AT E62419T1
Authority
AT
Austria
Prior art keywords
amide
active substances
pharmaceutical preparations
preparations containing
containing ester
Prior art date
Application number
AT88105821T
Other languages
English (en)
Inventor
Soonih Kim
Kazuhisa Takeda
Seiei Sasatani
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE62419T1 publication Critical patent/ATE62419T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88105821T 1987-04-13 1988-04-12 Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten. ATE62419T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8878587 1987-04-13
EP88105821A EP0287036B1 (de) 1987-04-13 1988-04-12 Pharmazeutische Zubereitungen, die Ester oder Amide als Wirkstoffe enthalten

Publications (1)

Publication Number Publication Date
ATE62419T1 true ATE62419T1 (de) 1991-04-15

Family

ID=13952501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88105821T ATE62419T1 (de) 1987-04-13 1988-04-12 Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.

Country Status (7)

Country Link
US (3) US4889723A (de)
EP (1) EP0287036B1 (de)
KR (1) KR880012221A (de)
AT (1) ATE62419T1 (de)
DE (1) DE3862337D1 (de)
ES (1) ES2033985T3 (de)
GR (1) GR3001762T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682253A1 (fr) 1991-10-07 1993-04-09 Commissariat Energie Atomique Sole chauffante destinee a assurer le chauffage d'un objet dispose a sa surface et reacteur de traitement chimique muni de ladite sole.
IT1263840B (it) * 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
KR20000005312A (ko) 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
EP0859603B1 (de) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
AU719076B2 (en) * 1996-12-19 2000-05-04 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
HK1040195B (zh) * 1998-08-19 2006-06-02 Skyepharma Canada Inc. 普鲁泊福的可注射水分散体
WO2000040219A1 (en) 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
MXPA01005370A (es) * 1999-09-30 2004-05-14 Penwest Pharmaceuticals Co Sistema de matriz de liberacion sostenida para farmacos altamente solubles.
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
US9730884B2 (en) * 2011-09-29 2017-08-15 Plx Opco Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45448B1 (en) * 1976-07-12 1982-08-25 Kali Chemie Pharma Gmbh Enterally highly-absorbable preparations of cardiac glycosides which by themselves are absorbable with difficulty and process for the production of such preparations
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
DE3042975A1 (de) * 1980-11-14 1982-09-09 Lucas Meyer GmbH & Co, 2000 Hamburg Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
DE3411910A1 (de) * 1984-03-30 1985-10-10 Warner-Lambert Co., Morris Plains, N.J. Galenische zubereitung
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4716178A (en) * 1985-07-22 1987-12-29 Riker Laboratories, Inc. Substituted di-t-butylphenols

Also Published As

Publication number Publication date
US5110602A (en) 1992-05-05
GR3001762T3 (en) 1992-11-23
KR880012221A (ko) 1988-11-26
EP0287036A3 (en) 1988-11-30
EP0287036B1 (de) 1991-04-10
DE3862337D1 (de) 1991-05-16
US4889723A (en) 1989-12-26
EP0287036A2 (de) 1988-10-19
US5004612A (en) 1991-04-02
ES2033985T3 (es) 1993-04-01

Similar Documents

Publication Publication Date Title
ATE62419T1 (de) Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ATE144135T1 (de) Desodorierende kosmetische mittel mit einem gehalt an fettsäuren
DE3172223D1 (en) Edible, pharmaceutical compositions and processes for making thereof
MA21182A1 (fr) Ester 2,3,5,6-tetrafluorobenzylique d'acide (+) 1r-trans-2,2-dimeghyl-3-(2,2 dichlorovinyl) -cyclopropane-carboxylique, son procede de preparation et composition insecticide le contenant.
GEP20012578B (en) (54) Heteroaryl Succinamides, Pharmaceutical Compositions Containing the Same and Methods for Treatment of the Diseases Caused by Metalloproteinase Activity
ATE99928T1 (de) Ester des retinols und/oder der retinsaeure enthaltende aerosol-inhalate.
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
DE69319440D1 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
ATE65397T1 (de) Pharmazeutische zusammensetzungen mit gehalt an einem derivat der 3-hydroxy-buttersaeure, ausgewaehlt aus den oligomeren dieser saeure und den estern dieser saeure oder dieser oligomere mit dem 1,3-butan-diol.
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
DK585889D0 (da) Farmaceutisk praeparat
DE68926115D1 (de) Verfahren zur behandlung von akne
GB8812653D0 (en) Pharmaceutical composition based on high concentration esters of docosahexaenoic acid
DE69325236D1 (de) Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure
PT95697A (pt) Processo para a preparacao de composicoes farmaceuticas contendo substancias antiandrogenicamente activas
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
ES2069915T3 (es) Dicarbonatos y uretanos de los acidos 4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracenocarboxilicos que tienen actividades terapeuticas.
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
BE887566A (fr) Nouveaux acides 2-amino-3-(alpha-hedroxybenzyl)-phenylacetiques et leur esters et amides, utiles notamment comme agents anti-inflammatoires, et compositions pharmaceutiques les contenant
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
HUT51105A (en) Pesticide comprising substituted acrylic acid ester derivatives as active ingredient and process for producing the active ingredients
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
FI914410A0 (fi) Kalciumupptagande inhibitorer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee